

Atli Thorarensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5646032/publications.pdf>

Version: 2024-02-01

14
papers

648
citations

759233

12
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

1002
citing authors

#	ARTICLE	IF	CITATIONS
1	The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115865.	3.0	29
2	PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. <i>ACS Chemical Biology</i> , 2019, 14, 1235-1242.	3.4	76
3	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10665-10699.	6.4	55
4	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2 <i>S</i> ,5 <i>R</i>)-5-((7 <i>H</i> -Pyrrolo[2,3- <i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1971-1993.	6.4	111
5	Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells. <i>ACS Chemical Biology</i> , 2017, 12, 2970-2974.	3.4	24
6	Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1-7.	3.3	30
7	Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free Energy Perturbation (FEP). <i>ChemMedChem</i> , 2016, 11, 217-233.	3.2	41
8	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. <i>Scientific Reports</i> , 2016, 6, 30859.	3.3	36
9	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. <i>ACS Chemical Biology</i> , 2016, 11, 3442-3451.	3.4	127
10	Target the More Druggable Protein States in a Highly Dynamic Protein-Protein Interaction System. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 35-45.	5.4	11
11	New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013. <i>Pharmaceutical Patent Analyst</i> , 2014, 3, 523-541.	1.1	7
12	ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. <i>ACS Chemical Biology</i> , 2014, 9, 1552-1558.	3.4	51
13	Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6545-6553.	2.2	28
14	Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 59-63.	2.8	22